Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

Affiliations

• ¹ Department of Neuropathology, University Medical Center, Göttingen, Germany. Electronic address: [email protected].
• ² Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden.
• ³ Department of Neurology, Institut Investigacions Biomediques, Hospital de Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas-CIBERNED, Madrid, Spain.
• ⁴ Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen S, Denmark.
• ⁵ Neurochemistry Laboratory, Department of Neurology, Faculty of Medicine, CHUC-Centro Hospitalar e Universitário de Coimbra, CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
• ⁶ Department of Neuroscience (DINOGMI), Clinical Neurology Unit, Genoa, Italy.
• ⁷ Centre for Memory Disturbances and Alzheimer's Centre-Laboratory of Clinical Neurochemistry, Department of Medicine, Section of Neurology, University of Perugia, Perugia, Italy.
• ⁸ Neuropsychopharmacology Unit, IRCCS Cento S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; Faculty of Psychology, eCampus University, Novedrate (Como), Italy.
• ⁹ Department of Neurology, University Medical Centre, Ljubljana, Slovenia.
• ¹⁰ Reference Centre for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
• ¹¹ Department of Neuroscience, Health Science Institute, Dokuz Eylül University, Izmir, Turkey.
• ¹² Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
• ¹³ Laboratory of Alzheimer´s Neuroimaging and Epidemiology, IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; Departments of Psychiatry and Internal Medicine, University Hospitals and University of Geneva, Geneva, Switzerland.
• ¹⁴ Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas-CIBERNED, Madrid, Spain; Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Sant Joan d´Alcant, Spain.
• ¹⁵ 3rd Neurology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
• ¹⁶ Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen S, Denmark; Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense C, Denmark.
• ¹⁷ Genomed, Diagnósticos de Medicina Molecular, Instituto de Medicina Molecular, Edificio Egas Moniz, Lisbon, Portugal.
• ¹⁸ Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.
• ¹⁹ Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
• ²⁰ Instituto de Medicina Molecular, Edificio Egas Moniz, Lisbon, Portugal; Instituto Gulbenkian de Ciência, Oeiras, Portugal.
• ²¹ Instituto de Medicina Molecular, Edificio Egas Moniz, Lisbon, Portugal.
• ²² BioLegend, Inc., Dedham, MA, USA.
• ²³ ADx NeuroSciences NV, Gent, Belgium.
• ²⁴ Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
• ²⁵ Department of Neuropathology, University Medical Center, Göttingen, Germany; Paracelsus-Elena-Klinik, Kassel, Germany; Department of Neurosurgery, University Medical Center, Göttingen, Germany.